Evidence map›Paper›PMID 30342839›Full record

ReviewTrends in neurosciences2019

Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.

Michaela E Johnson, Benjamin Stecher, Viviane Labrie, Lena Brundin, Patrik Brundin

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in neurosciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 173 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03775096 phase2active not recruitingnot on this map

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease

TypeinterventionalSponsorMichele Tagliati, MDRan2019 to 2026Enrolled15ConditionsREM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson DiseaseArmsCarvedilol
NCT05109364 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2022 to 2026Enrolled15ConditionsSymptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's DiseaseArmsTerazosin therapy
3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michaela E JohnsonCenter for Neurodegenerative Science, Van Andel Research Institute, 333 Bostwick Avenue, NE, Grand Rapids, MI 49503, USA; These authors contributed equally to this work.
Benjamin StecherTomorrow Edition, Toronto, Canada; These authors contributed equally to this work.
Viviane LabrieCenter for Neurodegenerative Science, Van Andel Research Institute, 333 Bostwick Avenue, NE, Grand Rapids, MI 49503, USA.
Lena BrundinCenter for Neurodegenerative Science, Van Andel Research Institute, 333 Bostwick Avenue, NE, Grand Rapids, MI 49503, USA.
Patrik BrundinCenter for Neurodegenerative Science, Van Andel Research Institute, 333 Bostwick Avenue, NE, Grand Rapids, MI 49503, USA. Electronic address: Patrik.Brundin@vai.org.

Funding

Linking Synucleinopathy and Dysfunction of Olfactory PathwaysR01DC016519 · NIDCD · VAN ANDEL RESEARCH INSTITUTE · PI MOORE, DARREN JOHN, WESSON, DANIEL W · 2017 to 2021
$2.8M
Does Microglial Activation Influence Propagation of Alpha-synuclein PathologyR21NS093993 · NINDS · VAN ANDEL RESEARCH INSTITUTE · PI BRUNDIN, PATRIK · 2016 to 2017
$523k
NIDCD NIH HHS R01 DC016519NINDS NIH HHS R21 NS093993
6 · The paper itself

Abstract

We hypothesize that Parkinson's disease (PD) pathogenesis can be divided into three temporal phases. During the first phase, 'triggers', such as viral infections or environmental toxins, spark the disease process in the brain and/or peripheral tissues. Triggers alone, however, may be insufficient, requiring 'facilitators' like peripheral inflammation for PD pathology to develop. Once the disease manifests, 'aggravators' spur further neurodegeneration and exacerbate symptoms. Aggravators are proposed to include impaired autophagy and cell-to-cell propagation of α-synuclein pathology. We believe clinical trials need to consider these three phases and target potential therapies at the appropriate stage of the disease process in order to be effective.

Indexed as

alpha-SynucleinAnimalsAutophagyBrainDisease Models, AnimalHumansNeuronsParkinson Diseasealpha-Synucleinclinical trialsgeneticsinflammationParkinson’s diseaseα-synuclein

Identifiers

PMID30342839
PMCPMC6623978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.